Add like
Add dislike
Add to saved papers

Toxicity of spinosad to temephos-resistant Aedes aegypti populations in Brazil.

The mosquito Aedes aegypti is the primary vector of different arboviruses and represents a major public health problem. Several Brazilian populations of Ae. aegypti have developed resistance to temephos, the most used organophosphate larvicide. New tools which are less harmful to the environment and safer for humans are becoming increasingly important to control this insect vector. Spinosad, an aerobic fermentation product of a soil actinobacteria, has a favorable environmental profile. It presents selective insecticide properties, a mechanism of action that differs from those of many synthetic chemical insecticides. The toxicity of spinosad and temephos to Aedes aegypti populations from Brazil, which were previously exposed to temephos, were investigated in this study. Larval susceptibility (LC50) to temephos varied from 3μg/L for Rockefeller up to 260 μg/L for Santana do Ipanema field derived population. Larval susceptibility (LC50) to spinosad varied from 23μg/L for Rockefeller up to 93μg/L for Marilia field derived population. In addition, a semi-field trial was performed to evaluate spinosad (NatularTM DT) initial efficacy and persistence toward four field-derived lineages and the Rockefeller lineage, used as an internal control. Spinosad was tested at 0.5mg active ingredient/L in 200L capacity water tanks. Mortality was recorded each 24 hours after exposition and tanks were further recolonized once per week with mortality being recorded daily for eight weeks. Spinosad provided a level equal or superior to 80% mortality during a seven to eight week evaluation period. The assessed populations did not present cross-resistance between spinosad and temephos in laboratory conditions. It demonstrates that spinosad may be a promising larvicide for the control of Ae. aegypti, especially for populations in which resistance to temephos has been detected.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app